Close Menu

NEW YORK (GenomeWeb) – Agilent Technologies announced today that it has agreed to acquire ACEA Biosciences for $250 million in cash.

Privately held ACEA, which is based in San Diego, has most recently developed a line of xCELLigence impedance-based, label-free, real-time cell analysis instruments that are used in immuno-oncology, pre-clinical drug discovery and development, as well as in basic academic research. The company also sells a line of NovoCyte and NovoCyte Quanteon high-performance benchtop flow cytometry systems.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US Food and Drug Administration has approved an RNA interference drug to treat acute hepatic porphyria.

Stephen Hahn, the nominee to lead the US Food and Drug Administration, underwent a Senate confirmation hearing yesterday, the Washington Post reports.

Gizmodo looks over the past decade of consumer DNA testing to find the field to be lacking.

In Nature this week: native RNA sequencing and analysis of a human poly(A) transcriptome, nanopore sequencing-based method to analyze short tandem repeat expansions, and more.